Efeito terapêutico do leite fermentado por Lactobacillus delbrueckii subsp. lactis CIDCA 133 em modelo de mucosite intestinal induzido pelo antineoplásico 5-fluorouracil

Abstract

Intestinal mucositis is a cytotoxic effect of antineoplastic drugs like 5-Fluorouracil (5-FU) characterized by ulceration, inflammation, diarrhea and intense abdominal pain being a serious issue in clinical medicine. The use of probiotics like Lactobacillus sp. could be helpful strategy to alleviate intestinal damage caused by 5-FU chemotherapy, due of its antiinflammatory and immunomodulatory properties in the gastrointestinal tract. The probiotic properties of Lactobacillus delbrueckii subsp. lactis CIDCA 133 have been only reported in in vitro studies. Thus, in this work we evaluated the therapeutic effect of this bacterial strain on 5-FU-induced intestinal mucositis model. For this, BALB/c mice were divided into four experimental groups and were fed daily by drinking non fermented milk or fermented milk containing Lactobacillus delbrueckii CIDCA 133 (7.5 × 107CFU/mL). In order to induce mucositis, the animals received a single intraperitoneal injection of 5-FU (300 mg/kg). The results showed that treatment with CIDCA 133 was able to prevent weight loss of animals, leukopeny, secretion of sIgA and inflammatory infiltrate. In addition, this bacterial strain was able to attenuate loss of intestinal length as well as the number of goblet cells. Protection against increased intestinal permeability was also observed with improvement in histological scores and tissue architecture. Regarding water and food intake, no differences were observed between the inflamed and treated groups. In conclusion, we demonstrated that CIDCA 133fermented milk treatment was able to prevent the adverse effects to the intestinal mucosa induced by 5-FU administration, revealing to be a promising therapeutic strategy in the treatment of intestinal mucositis.